Layton Mills has worked in the biotechnology and life sciences industries for over 15 years, developing significant experience across human and animal health in pharmaceutical and consumer healthcare. He also has extensive international business experience, having been involved in corporate business activities across Europe, Asia and North America, including government-led trade incentives with the Canberra Business Chamber.
Mr Mills spent nine years in the fast moving consumer goods industry and has successfully launched a number of consumer goods into the Australian market, achieving national distribution.
He was the co-founder and managing director of CannPal Animal Therapeutics, a pharmaceutical-focused animal health company researching the therapeutic benefits of medical cannabis for companion animals. He led the company through an IPO on the Australian Stock Exchange, followed by an acquisition by AusCann Group Holdings in 2021 where he served as chief executive until March 2023. Mr Mills is also the founder and managing director of Subgenix Lifesciences, an early-stage biotechnology company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs.
